Clinical trials: Estrogen Activity
Metastatic Breast Cancer
ER Reactivation Therapy for Breast Cancer
Before anti-estrogens such as tamoxifen were developed to treat estrogen receptor (ER)-positive breast cancer, high-dose estrogen therapies were used.
- Trial name
- POLLY (NCT02188745)
- Testing
- 17B-estradiol, Letrozole, Anastrozole
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Breast Cancer
Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer
This clinical trial is evaluating a drug called AC699 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer.
- Trial name
- NCT05654532
- Testing
- AC699
- Where
- 9 sites in United States
- Volunteers
- 100 people
- Sponsor
- Accutar Biotechnology Inc
Hormone
Effects of Infant Diets on Estrogen Activity and Development
This study, conducted at the Children's Hospital of Boston and the Brigham and Women's Hospital in Boston, will examine the natural history of infant development in the first year of life and how different types of infant feeding…
- Trial name
- NCT00340652
- Where
- 2 sites in United States
- Volunteers
- 157 people
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
Contraception
International Active Surveillance Study: Safety of Estrogen Estetrol (E4) Contraceptive Study (INAS-SEECS)
The combined oral contraceptive (COC) containing estetrol (E4) and drospirenone (DRSP) (E4/DRSP) is a novel oral contraceptive containing a fixed dose of E4 (14.2 mg) and DRSP (3 mg).
- Trial name
- INAS-SEECS (NCT06186271)
- Where
- Germany
- Volunteers
- 68,100 people
- Sponsor
- Center for Epidemiology and Health Research, Germany
Neoplasms, Breast
Lapatinib and Bevacizumab for Metastatic Breast Cancer
This study will examine the efficacy and safety of lapatinib and bevacizumab in patients with ErbB2-overexpressing breast cancer.
- Trial name
- NCT00444535
- Testing
- lapatinib, bevacizumab
- Where
- 9 sites in United States
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-)
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer.
- Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma
- Trial name
- NCT07318805
- Testing
- PF-08032562, Fulvestrant, Cetuximab
- Where
- 13 sites in United States
- Volunteers
- 260 people
- Sponsor
- Pfizer
Breast Cancer
A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer
This clinical trial is evaluating a drug called AC682 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer.
- Trial name
- NCT05080842
- Testing
- AC682
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- Accutar Biotechnology Inc
Contraception
Effect of Norgestrel 75 mcg on Cervical Mucus and Ovarian Activity During Perfect Use, After One Delayed Intake and After a Missed Pill
Norgestrel 75 mcg is a progestin-only pill (POP), which is a kind of oral birth control pill. To be effective in preventing pregnancy, this kind of birth control pill is supposed to be taken every day at the same time, without…
- Trial name
- NCT03585712
- Testing
- Norgestrel 0.075 mg
- Where
- 2 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- HRA Pharma
Metastatic Breast Cancer
Phase II Study of GTx024 in Women With Metastatic Breast Cancer
The primary efficacy analysis will be the clinical benefit at 6 months as measured by a modified Response Evaluation Criteria in Solid Tumors RECIST classification.
- Trial name
- NCT01616758
- Testing
- GTx-024 9mg
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- GTx
ER+ HER2- Advanced Breast Cancer
AZD9496 First Time in Patients Ascending Dose Study
This is a phase 1 open label multicentre study of AZD9496 administered orally in patients with advanced ER+ HER2 negative breast cancer.
- Trial name
- NCT02248090
- Testing
- AZD9496
- Where
- 6 sites in United States, South Korea and 1 more
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Systemic Lupus Erythematosus
Hormonal and Environmental Risk Factors for Developing Systemic Lupus Erythematosus: The Carolina Lupus (CLU) Study
Systemic lupus erythematosus (SLE) is severe, chronic, disabling autoimmune disease that significantly affects health status and quality of life.
- Trial name
- NCT00342095
- Where
- 6 sites in United States
- Volunteers
- 640 people, healthy volunteers welcome
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
Contraception
International Active Surveillance Study - Safety of Contraceptives: Role of Estrogens
The primary objective of the study is to assess the risks of short and long-term use of estradiol valerate/dienogest (EV/DNG) and of established oral contraceptives (OCs) in a study population that is representative for the…
- Trial name
- INAS-SCORE (NCT01009684)
- Where
- Germany
- Volunteers
- 50,203 people, healthy volunteers welcome
- Sponsor
- Center for Epidemiology and Health Research, Germany
Systemic Lupus Erythematosus
Serologically Active, Clinically Stable Systemic Lupus Erythematosus
The first part of this study will use the database of a large, ongoing NIH-sponsored lupus study, Safety of Estrogen in Lupus Erythematosus National Assessment.
- Trial name
- SACS-SLE (NCT00000421)
- Testing
- Prednisone
- Where
- 3 sites in United States
- Volunteers
- 154 people
- Sponsor
- NYU Langone Health
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8
Exercise Intervention After Cancer Treatment for Improving Health in Stage II-III Breast Cancer Survivors
This pilot trial studies how well exercise intervention after cancer treatment works in improving physical activity in stage II-III breast cancer survivors. An exercise intervention may promote regular physical activity.
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- PACT (NCT03523195)
- Testing
- Exercise Intervention, Informational Intervention, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
Postmenopausal Women
Resistance Exercise Training on Vascular and Physical Function in Postmenopausal Women
Postmenopausal women often face risks of vascular dysfunction and muscle deterioration due to estrogen deficiency. These changes significantly increase the risk of cardiovascular disease and mortality.
- Trial name
- NCT06958965
- Testing
- Resistance exercise training
- Where
- Taiwan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- National Yang Ming Chiao Tung University
Iron-deficiency, Inflammation
Iron and Muscular Damage: FEmale Metabolism and Menstrual Cycle During Exercise
This project is an observational controlled randomized counterbalance study. One hundred and three physically active and healthy women were selected to participate in the IronFEMME Study, of which 57 were eumenorrheic, 30 were…
- Conditions
- Iron-deficiency, Inflammation, Exercise Induced Iron-deficiency, Exercise Induced Muscle Damage
- Trial name
- IronFEMME (NCT04458662)
- Testing
- Interval running protocol / eccentric-based resistance exercise protocol
- Where
- Spain
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Universidad Politecnica de Madrid
Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors
The purpose of this study is to learn about the safety and effects of the study medicine (called PF-08165784) when given alone or together with other anti-cancer therapies.
- Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Metastatic Colorectal Adenocarcinoma
- Trial name
- NCT07897721
- Testing
- PF-08165784, Fulvestrant, Atirmociclib
- Volunteers
- 268 people
- Sponsor
- Pfizer
Endometrial Hyperplasia, Osteoporosis
Study Evaluating Safety and Efficacy of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women
The purpose of this study is to determine whether bazedoxifene/conjugated estrogens combinations are effective for the prevention of endometrial hyperplasia and for the prevention of osteoporosis in postmenopausal women.
- Trial name
- NCT00675688
- Testing
- Bazedoxifene/Conjugate Estrogens (CE), Raloxifene
- Volunteers
- 3,544 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Breast Cancer
Effects of Activity on Diabetes Risk Among Breast Cancer Survivors on Endocrine Therapy (ABIDE)
The aim of this study is to learn more about how physical activity and cardiorespiratory fitness are related to diabetes risk among breast cancer patients prescribed an endocrine therapy.
- Trial name
- ABIDE (NCT06830486)
- Testing
- No intervention
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Colorado, Denver
Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive
Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast
This randomized phase IIB trial studies how well tamoxifen or afimoxifene works in treating patients with estrogen receptor positive breast cancer. Estrogen can cause the growth of breast cancer cells.
- Trial name
- NCT02993159
- Testing
- Afimoxifene, Laboratory Biomarker Analysis, Tamoxifen Citrate
- Where
- 6 sites in United States
- Volunteers
- 100 people
- Sponsor
- Northwestern University